Daily Stock Analysis, CLDX, Celldex Therapeutics Inc, priceseries

Celldex Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
55.06
Close
54.39
High
56.11
Low
52.68
Previous Close
53.28
Daily Price Gain
1.11
YTD High
56.17
YTD High Date
Sep 10, 2021
YTD Low
15.37
YTD Low Date
Mar 29, 2021
YTD Price Change
35.29
YTD Gain
184.76%
52 Week High
56.17
52 Week High Date
Sep 10, 2021
52 Week Low
11.55
52 Week Low Date
Sep 24, 2020
52 Week Price Change
41.45
52 Week Gain
320.32%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 22. 2017
39.90
Oct 17. 2017
45.00
17 Trading Days
12.77%
Link
LONG
Mar 5. 2018
36.15
Mar 13. 2018
38.80
6 Trading Days
7.34%
Link
LONG
Aug 21. 2018
6.59
Sep 4. 2018
7.22
9 Trading Days
9.55%
Link
LONG
Jan 4. 2019
3.57
Feb 8. 2019
6.91
24 Trading Days
93.49%
Link
LONG
Sep 10. 2019
2.23
Sep 24. 2019
2.37
10 Trading Days
6.30%
Link
LONG
Apr 17. 2020
2.01
Apr 28. 2020
2.32
7 Trading Days
15.19%
Link
LONG
Jun 2. 2020
2.77
Jul 8. 2020
11.78
25 Trading Days
325.31%
Link
LONG
Sep 25. 2020
12.80
Oct 14. 2020
15.67
13 Trading Days
22.39%
Link
LONG
Nov 18. 2020
19.61
Dec 3. 2020
20.68
10 Trading Days
5.45%
Link
LONG
Jan 25. 2021
18.82
Mar 3. 2021
27.40
26 Trading Days
45.56%
Link
LONG
Apr 14. 2021
22.27
May 4. 2021
29.07
14 Trading Days
30.56%
Link
LONG
Jun 23. 2021
30.01
Jul 6. 2021
32.05
8 Trading Days
6.80%
Link
LONG
Jul 9. 2021
32.41
Jul 27. 2021
41.94
12 Trading Days
29.40%
Link
LONG
Aug 19. 2021
45.60
Sep 13. 2021
52.26
16 Trading Days
14.59%
Link
Company Information
Stock Symbol
CLDX
Exchange
NasdaqGS
Company URL
http://www.celldex.com
Company Phone
908-200-7500
CEO
Anthony S. Marucci
Headquarters
New Jersey
Business Address
53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ 08827
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000744218
About

Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.